Page 241 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
myeloma: three-year follow-up of CASTOR. Clin Lymphoma
Myeloma Leuk. 2020;20(8):509-518.
6. Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus
lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34(7):1875-1884.
7. Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low- dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055-1066.
8. Orlowski RZ, Moreau P, Niesvizky R, et al. Carfilzomib- dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups. Clin Lymphoma Myeloma Leuk. 2019;19(8):522-530.
9. Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(8):728-734.
10. Dimopoulos MA, Oriol A, Nahi H, et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label,
phase III trial. J Clin Oncol. 2023;41(8):1590-1599.
11. Sonneveld P, Chanan-Khan A, Weisel K, et al. Overall survival
with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. J Clin Oncol. 2023;41(8):1600-1609.
12. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
13. Knauf W, Aldaoud A, Hutzschenreuter U, et al. Survival of non- transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German Tumour Registry Lymphatic Neoplasms. Ann Hematol. 2018;97(12):2437-2445.
14. Klausen TW, Gregersen H, Abildgaard N, et al. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials. Leukemia. 2019;33(2):546-549.
15. Chari A, Romanus D, Palumbo A, et al. Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed/ refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):8-17.
Haematologica | 110 January 2025
233